Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study
Ultramicronized palmitoylethanolamide (um-PEA), a compound with antioxidant, anti-inflammatory and neuroprotective properties, appears to be a potential adjuvant treatment for early stages of Coronavirus disease 2019 (COVID-19). In our study, we enrolled 90 patients with confirmed diagnosis of COVID...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/2/253 |
| _version_ | 1797477289925017600 |
|---|---|
| author | Maria Albanese Giulia Marrone Agostino Paolino Manuela Di Lauro Francesca Di Daniele Carlo Chiaramonte Cartesio D’Agostini Annalisa Romani Alessandro Cavaliere Cristina Guerriero Andrea Magrini Nicola Biagio Mercuri Nicola Di Daniele Annalisa Noce |
| author_facet | Maria Albanese Giulia Marrone Agostino Paolino Manuela Di Lauro Francesca Di Daniele Carlo Chiaramonte Cartesio D’Agostini Annalisa Romani Alessandro Cavaliere Cristina Guerriero Andrea Magrini Nicola Biagio Mercuri Nicola Di Daniele Annalisa Noce |
| author_sort | Maria Albanese |
| collection | DOAJ |
| description | Ultramicronized palmitoylethanolamide (um-PEA), a compound with antioxidant, anti-inflammatory and neuroprotective properties, appears to be a potential adjuvant treatment for early stages of Coronavirus disease 2019 (COVID-19). In our study, we enrolled 90 patients with confirmed diagnosis of COVID-19 that were randomized into two groups, homogeneous for age, gender and BMI. The first group received oral supplementation based on um-PEA at a dose of 1800 mg/day for a total of 28 days; the second group was the control group (R.S. 73.20). At baseline (T0) and after 28 days of um-PEA treatment (T1), we monitored: routine laboratory parameters, inflammatory and oxidative stress (OS) biomarkers, lymphocytes subpopulation and COVID-19 serological response. At T1, the um-PEA-treated group presented a significant reduction in inflammation compared to the control group (CRP <i>p</i> = 0.007; IL-6 <i>p</i> = 0.0001; neutrophils to lymphocytes ratio <i>p</i> = 0.044). At T1, the controls showed a significant increase in OS compared to the treated group (FORT <i>p</i> = 0.05). At T1, the um-PEA group exhibited a significant decrease in D-dimer levels (<i>p</i> = 0.0001) and higher levels of IgG against SARS-CoV-2 (<i>p</i> = 0.0001) compared to the controls. Our data demonstrated, in a randomized clinical trial, the beneficial effects of um-PEA in both asymptomatic and mild-symptomatic patients related to reductions in inflammatory state, OS and coagulative cascade alterations. |
| first_indexed | 2024-03-09T21:15:29Z |
| format | Article |
| id | doaj.art-f809ad22d8134d10bc4f3c765562e449 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T21:15:29Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-f809ad22d8134d10bc4f3c765562e4492023-11-23T21:35:29ZengMDPI AGPharmaceuticals1424-82472022-02-0115225310.3390/ph15020253Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control StudyMaria Albanese0Giulia Marrone1Agostino Paolino2Manuela Di Lauro3Francesca Di Daniele4Carlo Chiaramonte5Cartesio D’Agostini6Annalisa Romani7Alessandro Cavaliere8Cristina Guerriero9Andrea Magrini10Nicola Biagio Mercuri11Nicola Di Daniele12Annalisa Noce13Neurology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, ItalyUOC of Internal Medicine-Center of Hypertension and Nephrology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, ItalyDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, ItalyUOC of Internal Medicine-Center of Hypertension and Nephrology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, ItalyPhD School of Applied Medical, Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, ItalyDepartment of Statistics, University of Rome Tor Vergata, 00133 Rome, ItalyDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, ItalyPHYTOLAB (Pharmaceutical, Cosmetic, Food Supplement, Technology and Analysis), DiSIA, University of Florence, Sesto Fiorentino, 50019 Florence, ItalyClinic Department of Gynecology Fabia Mater, 00171 Rome, ItalyUOC of Internal Medicine-Center of Hypertension and Nephrology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, ItalyDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, ItalyNeurology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, ItalyUOC of Internal Medicine-Center of Hypertension and Nephrology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, ItalyUOC of Internal Medicine-Center of Hypertension and Nephrology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, ItalyUltramicronized palmitoylethanolamide (um-PEA), a compound with antioxidant, anti-inflammatory and neuroprotective properties, appears to be a potential adjuvant treatment for early stages of Coronavirus disease 2019 (COVID-19). In our study, we enrolled 90 patients with confirmed diagnosis of COVID-19 that were randomized into two groups, homogeneous for age, gender and BMI. The first group received oral supplementation based on um-PEA at a dose of 1800 mg/day for a total of 28 days; the second group was the control group (R.S. 73.20). At baseline (T0) and after 28 days of um-PEA treatment (T1), we monitored: routine laboratory parameters, inflammatory and oxidative stress (OS) biomarkers, lymphocytes subpopulation and COVID-19 serological response. At T1, the um-PEA-treated group presented a significant reduction in inflammation compared to the control group (CRP <i>p</i> = 0.007; IL-6 <i>p</i> = 0.0001; neutrophils to lymphocytes ratio <i>p</i> = 0.044). At T1, the controls showed a significant increase in OS compared to the treated group (FORT <i>p</i> = 0.05). At T1, the um-PEA group exhibited a significant decrease in D-dimer levels (<i>p</i> = 0.0001) and higher levels of IgG against SARS-CoV-2 (<i>p</i> = 0.0001) compared to the controls. Our data demonstrated, in a randomized clinical trial, the beneficial effects of um-PEA in both asymptomatic and mild-symptomatic patients related to reductions in inflammatory state, OS and coagulative cascade alterations.https://www.mdpi.com/1424-8247/15/2/253SARS-CoV-2COVID-19um-PEAoral food supplementcytokines stormoxidative stress |
| spellingShingle | Maria Albanese Giulia Marrone Agostino Paolino Manuela Di Lauro Francesca Di Daniele Carlo Chiaramonte Cartesio D’Agostini Annalisa Romani Alessandro Cavaliere Cristina Guerriero Andrea Magrini Nicola Biagio Mercuri Nicola Di Daniele Annalisa Noce Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study Pharmaceuticals SARS-CoV-2 COVID-19 um-PEA oral food supplement cytokines storm oxidative stress |
| title | Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study |
| title_full | Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study |
| title_fullStr | Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study |
| title_full_unstemmed | Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study |
| title_short | Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study |
| title_sort | effects of ultramicronized palmitoylethanolamide um pea in covid 19 early stages a case control study |
| topic | SARS-CoV-2 COVID-19 um-PEA oral food supplement cytokines storm oxidative stress |
| url | https://www.mdpi.com/1424-8247/15/2/253 |
| work_keys_str_mv | AT mariaalbanese effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT giuliamarrone effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT agostinopaolino effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT manueladilauro effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT francescadidaniele effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT carlochiaramonte effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT cartesiodagostini effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT annalisaromani effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT alessandrocavaliere effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT cristinaguerriero effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT andreamagrini effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT nicolabiagiomercuri effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT nicoladidaniele effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy AT annalisanoce effectsofultramicronizedpalmitoylethanolamideumpeaincovid19earlystagesacasecontrolstudy |